ライフサイエンスコーパス: mesothelioma

1 a treatment group with a final diagnosis of mesothelioma).

2 n patients with previously treated malignant mesothelioma.

3 re also obtained for rare nasal melanoma and mesothelioma.

4 tients with PD-L1-positive malignant pleural mesothelioma.

5 tients with ASS1-deficient malignant pleural mesothelioma.

6 suppressor gene in pleural lesions preceding mesothelioma.

7 ducted investigating CPIs in lung cancer and mesothelioma.

8 s with previously treated advanced malignant mesothelioma.

9 to several cancers, in particular malignant mesothelioma.

10 signs of clinical activity in patients with mesothelioma.

11 ith a PI3K/mTOR dual inhibitor, GDC-0980, in mesothelioma.

12 specific and sensitive in immunostaining of mesothelioma.

13 for patients with advanced malignant pleural mesothelioma.

14 odesis, 87 assigned to VAT-PP) had confirmed mesothelioma.

15 eurodesis in patients with malignant pleural mesothelioma.

16 patients with extensive treatment-refractory mesothelioma.

17 iferation of merlin-deficient meningioma and mesothelioma.

18 ce, but also occurring as primary peritoneal mesothelioma.

19 FGFR1, FGF2, and FGF18 were overexpressed in mesothelioma.

20 SS1P is currently in clinical trials in mesothelioma.

21 ilica seemed to increase the risk of pleural mesothelioma.

22 ent of recurrent and/or unresectable pleural mesothelioma.

23 with exposure to asbestos from patients with mesothelioma.

24 ailable serum biomarker of malignant pleural mesothelioma.

25 ed persons as compared with 48 patients with mesothelioma.

26 rent age gradient were testicular cancer and mesothelioma.

27 ps and 1,026 patients with malignant pleural mesothelioma.

28 g to the development of diseases, especially mesothelioma.

29 aluated with respect to genotype and site of mesothelioma.

30 ivo against both epithelioid and sarcomatoid mesothelioma.

31 frequent genetic lesions in human malignant mesothelioma.

32 e target for therapeutic development against mesothelioma.

33 median survival of 27 months) for peritoneal mesothelioma.

34 is in an orthotopic mouse model of malignant mesothelioma.

35 or placebo in unresectable malignant pleural mesothelioma.

36 thetase 1 (ASS1)-negative cancers, including mesothelioma.

37 d eventual sporadic development of malignant mesothelioma.

38 th advanced ASS1-deficient malignant pleural mesothelioma.

39 helioma or RECIST version 1.1 for peritoneal mesothelioma.

40 improved PFS in patients with ASS1-deficient mesothelioma.

41 evelopment of a variety of tumours including mesotheliomas.

42 minantly associated with uveal melanomas and mesotheliomas.

43 pressor NF2, a frequent tumorigenic event in mesothelioma(10,11), rendered cancer cells more sensitiv

44 ignificantly higher in patients with pleural mesothelioma (105+/-7 ng per milliliter in the Detroit c

45 in-3 levels in plasma (from 92 patients with mesothelioma, 136 asbestos-exposed persons without cance

46 rt) than in asbestos-exposed persons without mesothelioma (14+/-1 ng per milliliter and 24+/-1 ng per

47 ) than in patients with effusions not due to mesothelioma (212+/-25 and 151+/-23 ng per milliliter, r

48 controls), effusions (from 74 patients with mesothelioma, 39 with benign effusions, and 54 with mali

49 ignificantly higher in patients with pleural mesothelioma (694+/-37 ng per milliliter in the Detroit

50 In patients suspected of having mesothelioma, a positive blood test for mesothelin at a

51 d clinical trial, the Arginine Deiminase and Mesothelioma (ADAM) study, was conducted between March 2

52 mice had a significantly higher incidence of mesothelioma after exposure to very low doses of asbesto

53 ophylactic radiotherapy in all patients with mesothelioma after large-bore thoracic interventions is

54 s, thereby increasing the risk of developing mesothelioma after minimal exposure.

55 r clinical registration trials for malignant mesothelioma: amatuximab in the first-line setting and a

56 inactivating mutations of BAP1 predispose to mesothelioma and certain other cancers.

57 s with measurable advanced malignant pleural mesothelioma and disease progression after one or two pr

58 anisms underlying the long latency period of mesothelioma and driving carcinogenesis are unknown.

59 h unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 were random

60 al trials for the treatment of patients with mesothelioma and lung cancer.

61 editary cancer syndrome with a high risk for mesothelioma and melanocytic tumors.

62 is mutated in several cancers, most notably mesothelioma and melanoma, where it is thought to promot

63 ciated cancers such as renal cell carcinoma, mesothelioma and meningioma, but not uveal melanoma.

64 in select human cancers, including malignant mesothelioma and meningioma.

65 A significant association between mesothelioma and MW exposure was observed after adjustme

66 ere associated with BAP1 syndrome, including mesothelioma and ocular/cutaneous melanomas, as well as

67 e tumor regression in patients with advanced mesothelioma and opens up the possibility that such an a

68 or suppressor gene predispose individuals to mesothelioma and other cancers.

69 ising candidates for monitoring and treating mesothelioma and other mesothelin-expressing cancers.

70 thelin is an emerging cell surface target in mesothelioma and other solid tumors.

71 Analogous to mesothelioma and ovarian carcinoma, a significant increa

72 d in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarc

73 Recent publications, particularly the MARS (Mesothelioma and Radical Surgery) feasibility study by T

74 itary cancer syndrome with increased risk of mesothelioma and uveal melanoma.

75 ted cancer syndrome that is characterized by mesothelioma and uveal melanoma.

76 rs or older who had pathologically confirmed mesothelioma and were deemed fit enough to undergo trimo

77 with a family history of cancers other than mesothelioma, and 153 asbestos-exposed individuals witho

78 logies from 123 patients (69 lung cancer, 25 mesothelioma, and 29 extrathoracic primary malignancies)

79 ancer, 93 patients with effusions not due to mesothelioma, and 43 healthy controls), effusions (from

80 bestos-exposed individuals develop malignant mesothelioma, and because mesothelioma clustering is obs

81 ective and selective therapeutic strategy in mesothelioma, and identifies mitochondrial morphology as

82 ients each with adrenocortical carcinoma and mesothelioma, and one patient each with malignant gangli

83 th pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis might be preferable c

84 P1) in two families with a high incidence of mesothelioma, and we observed somatic alterations affect

85 odermal origin, various types of carcinomas, mesotheliomas, and sarcomas as well as myeloid leukemias

86 dkn2a results in rapid, aggressive malignant mesotheliomas, and that deletion of Bap1 contributes to

87 PD-1/PD ligand 1 blockade in lung cancer and mesothelioma are being conducted.

88 ter efficacy than monotherapies in malignant mesothelioma are ongoing.

89 Non-small-cell lung cancer and mesothelioma are thoracic malignancies, which in their a

90 New therapeutic strategies for malignant mesothelioma are urgently needed.

91 Malignant mesotheliomas are highly aggressive tumors usually cause

92 Cardiac sarcomas and mesotheliomas are the most lethal PMCTs, with 1-, 3-, 5-

93 inicopathologic characteristics of malignant mesotheliomas arising in these patients have not been es

94 Furthermore, mesotheliomas arose at an accelerated rate in Bap1(+/-)

95 osine kinase receptor expressed in malignant mesothelioma as well as in a variety of cancers.

96 urthermore, BAP1 mutation carriers developed mesothelioma at an earlier age that was more often perit

97 New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize tr

98 germline BAP1 mutations in 2 of 26 sporadic mesotheliomas; both individuals with mutant BAP1 were pr

99 re also seen in other cancers including some mesothelioma, breast cancer, colorectal carcinoma, melan

100 f human antibodies that bind all subtypes of mesothelioma, but not normal mesothelium.

101 We developed a new mouse model of mesothelioma by bladder or intraperitoneal injection of

102 siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells.

103 cohorts, but were identified in nine of 150 mesothelioma cases (6%) with a family history of cancer.

104 PrP(C) is observed in human Merlin-deficient mesothelioma cell line TRA and in human Merlin-deficient

105 of FGFs and their receptors was analyzed in mesothelioma cell lines and tissue specimens.

106 tent anti-tumor cytotoxicity towards primary mesothelioma cell lines in vitro and an NCI-H226 xenogra

107 Mesothelioma cell lines were established, which showed l

108 rmation, and G1 cell cycle arrest in several mesothelioma cell lines, accompanied by apoptosis induct

109 n human mesothelioma, we examined nine human mesothelioma cell lines, and found that four of nine sho

110 o a more sarcomatoid phenotype in subsets of mesothelioma cell lines.

111 To identity novel mesothelioma cell surface antigens with broad subtype co

112 increased calretinin expression observed in mesothelioma cells and in certain colon cancer might be

113 maintenance of EphB4-expression in malignant mesothelioma cells and other IGF-II-secreting cancers (I

114 ted phage antibody display libraries on live mesothelioma cells and tissues following counterselectio

115 e that EphB4 protein expression in malignant mesothelioma cells depend upon a degradation rescue mech

116 data suggest that the malignant phenotype of mesothelioma cells depends on intact FGF signals, which

117 Mesothelioma cells from Bap1(+/-) mice showed biallelic

118 However, normal mesothelial cells and mesothelioma cells from Bap1(+/-) mice showed downregula

119 e we show that EphB4 expression in malignant mesothelioma cells is markedly decreased upon neutraliza

120 gether, our findings indicate that malignant mesothelioma cells rely on HMGB1, and they offer a precl

121 Malignant mesothelioma cells strongly expressed HMGB1 and secreted

122 stablishes an autocrine circuit in malignant mesothelioma cells that influences their proliferation a

123 Furthermore, mesothelioma cells that lack BAP1 are sensitive to EZH2

124 ependent growth of HMGB1-secreting malignant mesothelioma cells was inhibited in vitro by treatment w

125 ived primary metastatic breast cancer cells, mesothelioma cells, and lung cancer xenograft cells.

126 nd HER2 expression in NCI-H226 and MSTO-211H mesothelioma cells.

127 develop malignant mesothelioma, and because mesothelioma clustering is observed in some families, we

128 he interim analysis of the malignant pleural mesothelioma cohort.

129 Human antibodies targeting all subtypes of mesothelioma could be useful to image and treat this dea

130 inogenesis during the long latency period of mesothelioma development and shows that CNT and asbestos

131 rt CNTs into the pleural cavity, the site of mesothelioma development, produced asbestos-like length-

132 3 wk) for the treatment of malignant pleural mesothelioma did not result in survival benefit in the p

133 The vast majority of patients with mesothelioma die of their disease within 3 years.

134 ental models of diffuse malignant peritoneal mesothelioma (DMPM), a rapidly lethal disease, poorly re

135 ental models of diffuse malignant peritoneal mesothelioma (DMPM), a rare and rapidly fatal disease, p

136 a fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign e

137 are in favor of an increased risk of pleural mesothelioma for subjects exposed to both asbestos and M

138 with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk control

139 Unlike in WT mice, mesotheliomas from Bap1(+/-) mice did not require homozy

140 ian survival of only 12 weeks, and malignant mesotheliomas from these mice were consistently high-gra

141 RNA-seq analysis of malignant mesotheliomas from triple-CKO mice revealed enrichment o

142 , as well as other types of cancer including mesothelioma, glioma multiforme, breast, colorectal, ski

143 or cancer therapy, but their significance in mesothelioma has remained largely undefined.

144 of non-small cell lung cancer and malignant mesothelioma, has adverse effects including neutropenia,

145 y of life in patients with malignant pleural mesothelioma have, to our knowledge, not been assessed i

146 bladder; brain and nervous system; thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma; mu

147 In mesothelioma, immunotherapies being investigated include

148 or Cdkn2a to drive development of malignant mesothelioma in approximately 20% of double-CKO mice, an

149 e to asbestos is required for development of mesothelioma in BAP1 mutation carriers are not known.

150 significantly increase the risk of malignant mesothelioma in genetically predisposed individuals carr

151 doses of asbestos, doses that rarely induced mesothelioma in wild-type mice.

152 cant increase in the incidence of aggressive mesotheliomas in the two mouse models carrying clinicall

153 Notably, we also observed malignant mesotheliomas in two Bap1-mutant mice, but not in any wi

154 r Nf2 alone gave rise to few or no malignant mesotheliomas, inactivation of Bap1 cooperated with loss

155 Malignant pleural mesothelioma incidence continues to rise, with few avail

156 matic alterations affecting BAP1 in familial mesotheliomas, indicating biallelic inactivation.

157 Malignant mesothelioma is a deadly disease with limited therapeuti

158 Mesothelioma is a fatal tumor of the pleura and is stron

159 Malignant pleural mesothelioma is a highly aggressive cancer with poor pro

160 Pleural malignant mesothelioma is a therapy-resistant cancer affecting the

161 Human malignant mesothelioma is an aggressive and highly lethal cancer t

162 Malignant mesothelioma is an aggressive cancer largely associated

163 Malignant pleural mesothelioma is an aggressive malignancy characterized b

164 Mesothelioma is an aggressive malignancy generally assoc

165 Mesothelioma is caused by malignant transformation of th

166 Mesothelioma is diagnosed in approximately 2500 patients

167 notherapy in patients with malignant pleural mesothelioma is feasible, well-tolerated, and capable of

168 Mesothelioma is highly aggressive; its sarcomatoid varia

169 ating checkpoint blockade in lung cancer and mesothelioma is provided.

170 ldwide, but its capacity to induce malignant mesothelioma is still debated.

171 Malignant mesothelioma is strongly associated with asbestos exposu

172 However, why mesothelioma is the predominate malignancy in some BAP1

173 malignant mesothelioma, particularly pleural mesothelioma, is very poor.

174 d cytotoxicity when cocultured with a murine mesothelioma line that stably expresses mesothelin.

175 ing that predisposition of Bap1(+/-) mice to mesothelioma may be facilitated, in part, by cooperation

176 highly significant for patients with pleural mesothelioma (median survival 7.9 y versus 2.4 y, P = 0.

177 .0012), but not for patients with peritoneal mesothelioma (median survival 8.2 y versus 5.4 y, P = 0.

178 d malignant tumor types, including malignant mesothelioma, melanoma, and kidney carcinoma.

179 creas, adrenocortical, small bowel, sarcoma, mesothelioma, melanoma, gastric, and germ cell tumors.

180 l, ovarian, endometrial and prostate cancer, mesothelioma, melanoma, leukemias, and osteosarcoma.

181 AP1) gene has been linked to uveal melanoma, mesothelioma, meningioma, renal cell carcinoma and basal

182 l relationship established between malignant mesothelioma (MM) and asbestos exposure, the exact mecha

183 We have generated mouse models of malignant mesothelioma (MM) based upon disruption of the Bap1, Nf2

184 Malignant mesothelioma (MM) is a relatively rare but devastating t

185 Malignant mesothelioma (MM) is an aggressive cancer primarily diag

186 Malignant mesothelioma (MM) is an aggressive malignancy, highly re

187 Malignant mesothelioma (MM) is an aggressive tumor with no treatme

188 Malignant mesothelioma (MM) is an asbestos-induced cancer arising

189 ral, causes unprecedented rates of malignant mesothelioma (MM) mortality in some Turkish villages.

190 t of the micronutrient selenium on malignant mesothelioma (MM) progression, we cultured four differen

191 tabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials h

192 Malignant mesothelioma (MM), is an intractable disease with limite

193 Among malignant mesotheliomas (MM), the sarcomatoid subtype is associate

194 Malignant peritoneal mesothelioma (MPeM) is a rare cancer of the mesothelial

195 ring the progression of malignant peritoneal mesothelioma (MPeM), tumor nodules propagate diffusely w

196 nt mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tiss

197 Malignant pleural mesothelioma (MPM) has an overall poor prognosis and uns

198 rocedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across

199 Malignant pleural mesothelioma (MPM) is a highly aggressive and generally

200 Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with poo

201 Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with

202 Malignant pleural mesothelioma (MPM) is an aggressive cancer that is commo

203 Malignant pleural mesothelioma (MPM) is an aggressive cancer that occurs m

204 Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miR

205 Malignant pleural mesothelioma (MPM) is an aggressive malignancy associate

206 Malignant pleural mesothelioma (MPM) is an aggressive neoplasm associated

207 Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer with

208 Human malignant pleural mesothelioma (MPM) is considered a rare tumor, but recen

209 Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable rate of

210 tients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC)

211 exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors.

212 AR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM cells that lack or e

213 or volume in patients with malignant pleural mesothelioma (MPM).

214 e treatment of epithelioid malignant pleural mesothelioma (MPM).

215 treatment of unresectable malignant pleural mesothelioma (MPM).

216 as first-line treatment of malignant pleural mesothelioma (MPM).

217 ancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unclear if these resu

218 to be highly expressed in malignant pleural mesotheliomas (MPM), was detected in serum using an elec

219 Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivat

220 carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%]), cutaneous melanoma (n = 38

221 .8%), followed by lymphomas (n=150, 27%) and mesotheliomas (n=44, 8%).

222 s were anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small-cell lung,

223 9)m)Tc (((9)(9)m)Tc-M40) in murine models of mesothelioma of both epithelioid (M28) and sarcomatoid (

224 tients with chemotherapy-resistant malignant mesothelioma of the pleura or peritoneum.

225 after injection, which was due to peritoneal mesothelioma, on the basis of tumor morphology and immun

226 Malignant mesothelioma onset was rapid in triple-CKO mice, with a

227 Among 148 patients with mesothelioma or ovarian, pancreatic, non-small-cell lung

228 olid Tumors (RECIST) version 1.0 for pleural mesothelioma or RECIST version 1.1 for peritoneal mesoth

229 , and 54 with malignant effusions not due to mesothelioma), or both.

230 uch as mesothelin, which is overexpressed in mesothelioma, ovarian, lung, breast, and pancreatic canc

231 d cancer target known to be overexpressed in mesothelioma, ovarian, lung, breast, and pancreatic canc

232 Survival from malignant mesothelioma, particularly pleural mesothelioma, is very

233 hich are all implicated in malignant pleural mesothelioma pathogenesis.

234 Accordingly, HMGB1 levels in malignant mesothelioma patient sera were higher than that found in

235 However, to date, we found that none of the mesothelioma patients carrying germline BAP1 mutations w

236 o accurately predict the overall survival of mesothelioma patients from whole-slide digitized images,

237 Collectively, these findings suggest that mesothelioma patients presenting with a family history o

238 ncidence and associated clinical features in mesothelioma patients with a family history of cancer ha

239 ned the germline BAP1 mutation status of 150 mesothelioma patients with a family history of cancer, 5

240 ited improved long-term survival compared to mesothelioma patients without BAP1 mutations.

241 to measure serum mesothelin concentration in mesothelioma patients, indicating its potential use for

242 esected tumor, and FNA were analyzed from 13 mesothelioma patients.

243 seen with exosomes from pleural effusions of mesothelioma patients.

244 ssociation between pleural diffuse malignant mesothelioma (PDMM) and chest radiation for lymphoma.

245 other cancers may also be involved and that mesothelioma predominates upon asbestos exposure.

246 anced, recurrent ovarian cancer or malignant mesothelioma received anetumab ravtansine at the maximum

247 Ten patients with malignant pleural mesothelioma received metronomic cyclophosphamide and de

248 predicts survival in patients with malignant mesothelioma receiving high-dose pembrolizumab.

249 tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical practic

250 asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure.

251 Research UK (CRUK/04/003), the June Hancock Mesothelioma Research Fund, and Guy's and St Thomas' NHS

252 Moreover, late diagnosis means that mesothelioma research is commonly focused on end-stage d

253 lost in both spontaneous ovarian tumors and mesotheliomas, resulting in the loss of Bap1 expression.

254 In end-stage mesothelioma, silencing of p16/Ink4a is sustained and de

255 We observed an excess of death due to mesothelioma (SMR = 2.24, 95% confidence interval (CI):

256 In addition to mesothelioma, some BAP1 mutation carriers developed uvea

257 A tissue microarray analysis of 198 human mesothelioma specimens showed that 33% of cases had redu

258 y population, because type of control group, mesothelioma stage, and histologic subtype significantly

259 s, cause-specific mortality was elevated for mesothelioma (standardized mortality ratio (SMR) = 2.85,

260 ting that mTOR activation is common in human mesothelioma, suggesting that it is a potential therapeu

261 NF2 tumors but not with malignant NF2 mutant mesotheliomas, suggesting that senescence may underlie t

262 icantly higher incidence of asbestos-induced mesothelioma than wild-type (WT) littermates (73% vs. 32

263 wide characterization of pathways altered in mesothelioma that could be potentially exploited to desi

264 bers into the pleural cavity of mice induces mesothelioma that exhibits common key pro-oncogenic mole

265 In small cell lung cancer and mesothelioma, the efficacy of checkpoint inhibition has

266 omparison of patients with and those without mesothelioma, the receiver-operating-characteristic curv

267 was to evaluate, in patients with malignant mesothelioma, the relationship between inherited loss-of

268 Except for malignant mesotheliomas, the role of NF2 mutation or inactivation

269 bestos-induced inflammatory lesions precedes mesothelioma; this results in silencing of Cdkn2a (Ink4a

270 g to the death of more than one patient were mesothelioma (three [1%] patients in the tremelimumab gr

271 nirradiated tumors in a concomitant model of mesothelioma through systemic activation of cytotoxic T

272 lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmo

273 their use of a murine model of human pleural mesothelioma to explore potential factors that limit CAR

274 reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, w

275 g a novel therapeutic approach for malignant mesothelioma treatment.

276 f Foxp3(+) regulatory T cells (Tregs) in the mesothelioma tumor microenvironment after nonablative ol

277 ended survival and a 95-99% reduction in the mesothelioma tumor volume, in comparison with vehicle-tr

278 ealth Organization classification subdivides mesothelioma tumors into three histological types: epith

279 mouse model to assess its susceptibility to mesothelioma upon chronic exposure to asbestos.

280 gnancies in their lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

281 bined with cyclophosphamide in patients with mesothelioma was safe, the only side effect being modera

282 d a high incidence (22/26, 85%) of malignant mesotheliomas was observed in Bap1;Nf2;Cdkn2a (triple)-C

283 Using an orthotopic mouse model of pleural mesothelioma, we determined that relatively high doses o

284 SC2 loss was a common genetic event in human mesothelioma, we examined nine human mesothelioma cell l

285 In mesothelioma, we identified a highly specific tumor cell

286 tients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in six countr

287 ents with histologically confirmed malignant mesothelioma were evaluated for inherited mutations in t

288 women and 29 men) with unresectable pleural mesothelioma were treated with repetitive transarterial

289 No spontaneous mesotheliomas were seen in unexposed Bap1(+/-) mice foll

290 sent in the serum of patients with malignant mesothelioma, which could negatively affect the response

291 help to identify individuals at high risk of mesothelioma who could be targeted for early interventio

292 unresectable pleural or peritoneal malignant mesothelioma who had progressed after one or two previou

293 s of patients with histocytologically proven mesothelioma who had undergone large-bore pleural interv

294 In a comparison of patients with early-stage mesothelioma with asbestos-exposed persons, the sensitiv

295 Patients with pleural mesothelioma with inherited mutations in DNA repair and

296 r with any subtype of confirmed or suspected mesothelioma with pleural effusion, recruited from 12 ho

297 atment of mice with malignant ascites due to mesothelioma with rapamycin led to a marked reduction in

298 f Bap1, Nf2, and Cdkn2a result in aggressive mesotheliomas, with Bap1 loss contributing to tumorigene

299 ons and aberrant BAP1 expression in sporadic mesotheliomas without germline mutations.

300 tion in vivo reduced the growth of malignant mesothelioma xenografts in severe-combined immunodeficie